ArticleParasites & vectors2026
Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine heartworm (Dirofilaria immitis), a filarial parasite endemic in many countries worldwide, can cause life-threatening disease in dogs if left untreated. Two laboratory studies and one field study were conducted to evaluate the efficacy of Credelio Quattro, a novel chewable tablet containing moxidectin in combination with lotilaner, praziquantel and pyrantel, for the prevention of heartworm disease caused by D. immitis.
methodsIn the laboratory studies, dogs were inoculated with 50 D. immitis L3 larvae on Day - 30. Eight dogs per group were randomized to receive either a placebo or Credelio Quattro at the minimum effective dosage of 0.02 mg/kg moxidectin, 20 mg/kg lotilaner, 5 mg/kg praziquantel, and 5 mg/kg pyrantel on Day 0. One of the studies also included a lotilaner-only treated group to demonstrate non-interference. Efficacy was evaluated ~ 150 days post-inoculation utilizing adult heartworm counts collected at necropsy. The field study enrolled client-owned dogs, ≥ 8 eight weeks of age, weighing at least 1.5 kg, from 13 geographically diverse veterinary clinics throughout the USA. Dogs were randomized in a 1:1 ratio to receive either Credelio Quattro or a positive control product, Simparica Trio
resultsIn both laboratory studies, no adult heartworms were collected from any of the dogs treated with a single dose of Credelio Quattro. In contrast, all dogs treated with placebo (range 13-40) or lotilaner-only (range 9-42) had adults present. A total of 372 dogs were enrolled in the field study (191 Credelio Quattro, 181 Simparica Trio). At the end of the study, no dogs from either treatment group tested positive for adult heartworms. Credelio Quattro was well tolerated in all studies.
conclusionsThe laboratory studies demonstrated Credelio Quattro as 100% effective for the prevention of heartworm disease caused by D. immitis in dogs. Additionally, no dogs in the field study tested positive for adult heartworm infection after 11 consecutive monthly doses of Credelio Quattro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.